ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 815

Lys63-Polyubiquitination By the E3 Ligase Casitas B-Lineage Lymphoma-b Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus

Diana Gómez-Martín1, Jorge Alcocer-Varela1, Jorge Romo-Tena1, Ana Barrera-Vargas1 and Javier Merayo-Chalico2, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lupus, T-Regulatory Cells and kinase

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The interplay between effector and regulatory T cells (Tregs) is a key element among peripheral tolerance mechanisms in Systemic Lupus Erythematosus (SLE). Resistance to suppression has been acknowledged as part of the defects shown by lupus T cells. The E3 ligase Cbl-b has been shown to modulate T cell unresponsiveness in SLE. However its role in peripheral Tregs tolerance has not been addressed. The aim of this study was to assess Cbl-b expression and its relationship to the resistance to suppression phenotype, as well as the ubiquitination profile in SLE.

Methods:

We included 30 SLE patients (20 with active disease and 10 with clinical remission) and 30 age and gender matched healthy controls. Peripheral blood mononuclear cells were isolated by density-gradient sedimentation. Effector (CD4+CD25–) and Tregs (CD4+CD25+CD127–) were purified by magnetic selection. The expression of Cbl-b and the ubiquitination profile were analyzed by western blot. Proliferative responses were assessed in allogeneic and autologous cocultures by CFSE method. Differences were assessed by t Student test. p<0.05 was considered as statistically significant.

Results:

We found decreased Cbl-b expression in Tregs from SLE patients in comparison to healthy controls (1.1±0.9 vs 2.5±1.8+6, p=0.003), which was associated with resistance to suppression in proliferation assays (r=0.633, p=0.039). This phenomenon was related to a differential polyubiquitination profile characterized by deficient expression of Lys63 (K63) substrates in regulatory T cells from SLE patients when compared to healthy controls. We analyzed different signaling molecules that are prone to K63 regulation and found increased expression of phosphorylated STAT3 (pSTAT3) in T cells from SLE patients in comparison to healthy controls.

Conclusion:  Our data suggest that Cbl-b is able to regulate the interplay between effector and Tregs, particularly, the resistance to suppression by regulating the K63 polyubiquitination profile in T cells from SLE patients. Moreover, deficient K63 polyubiquitination mainly of STAT3 is associated to the enhanced pSTAT3 expression and might play a role in the maintenance of resistance to suppression in SLE, as has been previously reported for other autoimmune diseases.


Disclosure: D. Gómez-Martín, None; J. Alcocer-Varela, None; J. Romo-Tena, None; A. Barrera-Vargas, None; J. Merayo-Chalico, None.

To cite this abstract in AMA style:

Gómez-Martín D, Alcocer-Varela J, Romo-Tena J, Barrera-Vargas A, Merayo-Chalico J. Lys63-Polyubiquitination By the E3 Ligase Casitas B-Lineage Lymphoma-b Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/lys63-polyubiquitination-by-the-e3-ligase-casitas-b-lineage-lymphoma-b-modulates-peripheral-regulatory-t-cell-tolerance-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lys63-polyubiquitination-by-the-e3-ligase-casitas-b-lineage-lymphoma-b-modulates-peripheral-regulatory-t-cell-tolerance-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology